𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Ifosfamide + mitoxantrone in advanced breast cancer previously treated with anthracyclines

✍ Scribed by Joaquin Bellmunt; Serafin Morales; Matilde Navarro; Luis-Alfonso Solé

Publisher
Springer
Year
1990
Tongue
English
Weight
385 KB
Volume
26
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

First-line combination chemotherapy with
First-line combination chemotherapy with mitoxantrone and cyclophosphamide in advanced breast cancer
✍ P. Periti; G. Robustelli Delia Cuna; F. Pannuti; T. Mazzei; P. Preti; A. Martoni 📂 Article 📅 1985 🏛 Springer US 🌐 English ⚖ 312 KB

In this study, 30 evaluable patients with advanced carcinoma of the breast were treated with cyclophosphamide 600 mg/m2 i.v. followed one day later with mitoxantrone (Novantrone; dihydroxyanthracenedione) 16 mg/m2 i.v. Drug treatment was repeated every 3-4 weeks, for a maximum of 12 cycles. The over

Phase II trial of ifosfamide/mesna and m
Phase II trial of ifosfamide/mesna and mitoxantrone in previously treated patients with non-Hodgkin's lymphoma: Cancer and leukemia group B study 8753
✍ Case, Delvyn C. ;Santarelli, Maria Teresa ;Carey, Robert W. ;Anderson, James ;Go 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 461 KB

## Abstract Ifosfamide (2.0 g/m^2^ intravenously/day × 3) with mesna (400 mg/m^2^ intravenously q 4 h daily × 3) was combined with mitoxantrone (14 mg/m^2^ intravenously × 1) and given on a 3 week schedule to patients with previously treated non‐Hodkgin's lymphoma. In 45 eligible/evaluable patients

Adriamycin, vincristine, dibromodulcitol
Adriamycin, vincristine, dibromodulcitol, and hexamethylmelamine in advanced previously treated breast cancer: An ECOG pilot study
✍ Taylor, Samuel G. ;Wolter, Janet 📂 Article 📅 1981 🏛 John Wiley and Sons 🌐 English ⚖ 155 KB

## Abstract A combination of adriamycin, vincristine, dibromodulcitol, and hexamethylmelamine was piloted in patients with advanced breast cancer who had failed prior CMFP chemotherapy, as a part of ongoing trials by the Eastern Cooperative Oncology Group to improve second‐line chemotherapy for thi

Vincristine, doxorubicin and mitomycin (
Vincristine, doxorubicin and mitomycin (VAM) in patients with advanced breast cancer previously treated with cyclophosphamide, methotrexate and fluorouracil (CMF)
✍ Sharon K. Shipp; Hyman B. Muss; Mary Alice Westrick; M. Robert Cooper; V. Jackso 📂 Article 📅 1983 🏛 Springer 🌐 English ⚖ 383 KB

Thirty-six evaluable patients with advanced breast cancer who had failed prior CMF therapy [15 (42%) as adjuvant treatment and 21 (58%) for advanced disease] were treated with a combination of vincristine, doxorubicin, and mitomycin (VAM). There was one CR and 10 PR, giving a response rate of 31% (P